In large clinical trials, ALT elevation was common, occurring in 39–61% of patients (G3/4: 2–5%), and in clinical trials and post-marketing experiences, the treatment has been associated with liver failure or death (0.3%). The gene discussed is GPT; the disease is Hepatic failure.